Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 19 Mar, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Articles
- Jeff Bezos Seeks $100 Billion to Transform Manufacturing with AI-Based Automation
- Americans Think Trump Lying About Not Sending Ground Troops to Mideast
- Takaichi Pressed to Join Hormuz Escort Service with Pearl Harbor Comparison
- Xiaomi's Lei Jun Quadruples AI Budget to $8.7 Billion As MiMo-V2-Pro Excites Developers
- Samsung to Supply HBM4 Chips for OpenAI's Custom Processor Project
- OpenClaw Craze Turns Ordinary Chinese into 'Lobster' Farmers
- Rivian Gets $1.25 Billion Injection from Uber in Robotaxi Deal
- Xiaomi Unveils Updated SU7 at $31,870 in Challenge to Tesla
- Ben & Don Begin Parting Company As Don Seeks Elusive Off-Ramp
- Angry Kpop Fans Crash S. Korea's Pension Fund Support Server